阿利莫克洛在快速进展型SOD1肌萎缩侧索硬化中的随机双盲安慰剂对照试验
这项双盲安慰剂对照试验将快速进展型SOD1突变肌萎缩侧索硬化患者按1:1随机分配接受阿利莫克洛200 mg每日三次或匹配安慰剂治疗至多12个月,主要结局为安全性和耐受性。38例受试者随机化,36例纳入预设意向治疗分析。阿利莫克洛组生存、ALSFRS-R和FEV6下降及CAFS均数值上倾向获益,但置信区间宽,研究不足以判定或排除重要治疗获益。
要点
- 阿利莫克洛200 mg每日三次治疗至多12个月安全且耐受良好,不良事件不常见且多为轻度。
- 校正利鲁唑和基线ALSFRS-R后,生存风险比为0.77(95%CI 0.32-1.80)。
- ALSFRS-R和FEV6下降斜率组间差异分别为0.5分/月(95%CI -0.63至1.63)和1.24%预计值/月(95%CI -2.77至5.25)。
核心结论
- 本研究提供II级证据表明阿利莫克洛200 mg每日三次治疗至多12个月安全且耐受良好。
- 尽管研究未针对治疗效果进行效力计算,但各预设疗效结局指标结果的一致性提示阿利莫克洛可能存在治疗获益。
- 研究缺乏精确度以判定或排除阿利莫克洛的重要治疗获益。
研究设计与样本
- 双盲、安慰剂对照试验,将快速进展型SOD1突变肌萎缩侧索硬化患者按1:1随机分配接受阿利莫克洛200 mg每日三次或匹配安慰剂治疗至多12个月。
- 研究程序采用现场与远程评估相结合的方式进行。
- 主要结局为安全性和耐受性,次要结局为疗效,以生存为主要疗效指标。
- 其他疗效指标包括修订版肌萎缩侧索硬化功能评定量表(ALSFRS-R)和6秒用力呼气量占预计值百分比(FEV6)的下降速率,以及功能和生存综合评估(CAFS)。
- 38例受试者随机化,36例(安慰剂19例,阿利莫克洛17例)纳入预设意向治疗分析。
主要发现
- 除呼吸功能外,两组基线特征总体均衡。
- 不良事件不常见,通常为轻度,且被认为不太可能或与研究药物无关。
- 校正利鲁唑和基线ALSFRS-R后,生存倾向阿利莫克洛,风险比为0.77(95%置信区间0.32-1.80)。
- 阿利莫克洛组ALSFRS-R和FEV6下降更慢,治疗差异分别为0.5分/月(95%置信区间-0.63至1.63)和1.24%预计值/月(95%置信区间-2.77至5.25)。
- CAFS同样倾向阿利莫克洛。
关键数值与推荐
- 本研究提供II级证据表明阿利莫克洛200 mg每日三次治疗至多12个月安全且耐受良好。
- 研究缺乏精确度以判定或排除阿利莫克洛的重要治疗获益。
临床怎么用
- 原文未据此给出推荐。
局限性
- 研究缺乏精确度以判定或排除阿利莫克洛的重要治疗获益。
- 尽管研究未针对治疗效果进行效力计算,但各预设疗效结局指标结果的一致性提示阿利莫克洛可能存在治疗获益。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To examine the safety and tolerability as well as the preliminary efficacy of arimoclomol, a heat shock protein co-inducer that promotes nascent protein folding, in patients with rapidly progressive SOD1 amyotrophic lateral sclerosis (ALS). METHODS: This was a double-blind, placebo-controlled trial in which patients with rapidly progressive SOD1-mutant ALS were randomized 1:1 to receive arimoclomol 200 mg tid or matching placebo for up to 12 months. Study procedures were performed using a mix of in-person and remote assessments. Primary outcome was safety and tolerability. Secondary outcome was efficacy, with survival as the principal measure. Additional efficacy measures were the rates of decline of the Revised ALS Functional Rating Scale (ALSFRS-R) and percent predicted forced expiratory volume in 6 seconds (FEV6), and the Combined Assessment of Function and Survival (CAFS). RESULTS: Thirty-eight participants were randomized. Thirty-six (19 placebo, 17 arimoclomol) were included in the prespecified intent-to-treat analysis. Apart from respiratory function, groups were generally well-balanced at baseline. Adverse events occurred infrequently, and were usually mild and deemed unlikely or not related to study drug. Adjusting for riluzole and baseline ALSFRS-R, survival favored arimoclomol with a hazard ratio of 0.77 (95% confidence interval [CI] 0.32-1.80). ALSFRS-R and FEV6 declined more slowly in the arimoclomol group, with treatment differences of 0.5 point/month (95% CI -0.63 to 1.63) and 1.24 percent predicted/month (95% CI -2.77 to 5.25), respectively, and the CAFS similarly favored arimoclomol. CONCLUSIONS: This study provides Class II evidence that arimoclomol is safe and well-tolerated at a dosage of 200 mg tid for up to 12 months. Although not powered for therapeutic effect, the consistency of results across the range of prespecified efficacy outcome measures suggests a possible therapeutic benefit of arimoclomol. CLINICALTRIALSGOV IDENTIFIER: NCT00706147. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that arimoclomol is safe and well-tolerated at a dosage of 200 mg tid for up to 12 months. The study lacked the precision to conclude, or to exclude, an important therapeutic benefit of arimoclomol.
引用
- Benatar M, Wuu J, Andersen PM, et al. Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive SOD1 ALS. Neurology. 2018. PMID: 29367439. doi:10.1212/WNL.0000000000004960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。